These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 33655614)
21. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach. Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135 [TBL] [Abstract][Full Text] [Related]
22. Advances Toward COVID-19 Therapies Special Issue. Neamati N J Med Chem; 2022 Feb; 65(4):2713-2715. PubMed ID: 35138859 [No Abstract] [Full Text] [Related]
23. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease. Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669 [TBL] [Abstract][Full Text] [Related]
24. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. Deshmukh MG; Ippolito JA; Zhang CH; Stone EA; Reilly RA; Miller SJ; Jorgensen WL; Anderson KS Structure; 2021 Aug; 29(8):823-833.e5. PubMed ID: 34161756 [TBL] [Abstract][Full Text] [Related]
25. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives. Citarella A; Dimasi A; Moi D; Passarella D; Scala A; Piperno A; Micale N Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759739 [TBL] [Abstract][Full Text] [Related]
26. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor. Jiang Y; Wu Y; Wang J; Ma Y; Yu H; Wang Z Curr Med Chem; 2024; 31(38):6204-6226. PubMed ID: 38529602 [TBL] [Abstract][Full Text] [Related]
27. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease. Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115 [TBL] [Abstract][Full Text] [Related]
28. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies. Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299 [TBL] [Abstract][Full Text] [Related]
29. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors. Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337 [TBL] [Abstract][Full Text] [Related]
30. An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease. Samrat SK; Kumar P; Liu Y; Chen K; Lee H; Li Z; Chen Y; Li H Viruses; 2024 Aug; 16(8):. PubMed ID: 39205213 [TBL] [Abstract][Full Text] [Related]
31. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19. Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348 [TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 M Rut W; Groborz K; Zhang L; Sun X; Zmudzinski M; Pawlik B; Wang X; Jochmans D; Neyts J; Młynarski W; Hilgenfeld R; Drag M Nat Chem Biol; 2021 Feb; 17(2):222-228. PubMed ID: 33093684 [TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome. Sardanelli AM; Isgrò C; Palese LL Molecules; 2021 Mar; 26(5):. PubMed ID: 33807773 [TBL] [Abstract][Full Text] [Related]
34. Screening of M Altomare A; Baron G; Cambiaghi G; Ferrario G; Zoanni B; Della Vedova L; Fumagalli GM; D'Alessandro S; Parapini S; Vittorio S; Vistoli G; Riso P; Carini M; Delbue S; Aldini G Molecules; 2024 Jun; 29(11):. PubMed ID: 38893578 [TBL] [Abstract][Full Text] [Related]
35. Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2. Chen Y; Yang WH; Chen HF; Huang LM; Gao JY; Lin CW; Wang YC; Yang CS; Liu YL; Hou MH; Tsai CL; Chou YZ; Huang BY; Hung CF; Hung YL; Wang WJ; Su WC; Kumar V; Wu YC; Chao SW; Chang CS; Chen JS; Chiang YP; Cho DY; Jeng LB; Tsai CH; Hung MC J Biol Chem; 2022 Mar; 298(3):101658. PubMed ID: 35101449 [TBL] [Abstract][Full Text] [Related]